# Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial)

Study · id `cardio:ct-nct07846579` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07846579](<https://clinicaltrials.gov/study/NCT07846579>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07846579

Browse, organ or system: Blood vessels  
Browse, condition area: Risk and prevention  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07846579. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2028-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07846579, source copy `cardio:ctgov-nct07846579-2026-09-29`, retrieved 2026-10-31)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07846579, source copy `cardio:ctgov-nct07846579-2026-09-29`, retrieved 2026-10-31)
- Primary completion: 2028-12-01 (anticipated) (ClinicalTrials.gov record NCT07846579, source copy `cardio:ctgov-nct07846579-2026-09-29`, retrieved 2026-10-31)
- Completion: 2029-02-01 (anticipated) (ClinicalTrials.gov record NCT07846579, source copy `cardio:ctgov-nct07846579-2026-09-29`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07846579-2026-09-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial)
- Acronym: CLEAR
- Condition: Benign Prostatic Hyperplasia
- Intervention (Drug): Tamsulosin hydrochloride 0.2 mg
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai East Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Orthostatic hypotension (`cardio:orthostatic-hypotension`)
- Registry lists this organization as the lead sponsor: Shanghai East Hospital (`cardio:org-shanghai-east-hospital`)

## Provenance

Content hash: 3224d99b2bc7b4e49d7dd533910a912733177a4e570b88f7a2214cdfcdd77af3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
